Search for content, post, videos

Novo Nordisk’s Fiasp approved in Europe for adolescents and children

Mads Krogsgaard Thomsen
The European Commission has granted an extension of the indication for Fiasp (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and children (aged one year and above). This complements the previous indication, which covered adults only. “We are very pleas
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.